Loading clinical trials...
Loading clinical trials...
A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema
Conditions
Interventions
Kamada AAT for inhalation
Placebo
Locations
12
Canada
Inspiration Research Limited
Toronto, Canada
Seymour Health Centre
Vancouver, Canada
Gentofte Hospital
Hellerup, Denmark
Universitätsklinikum des Saarlandes
Homburg/Saar, Germany
Universitatsklinikum Gieben und Marburg
Marburg, Germany
Beaumont Hospital
Dublin, Ireland
Start Date
December 1, 2009
Primary Completion Date
November 1, 2014
Completion Date
June 1, 2015
Last Updated
November 29, 2019
NCT06891755
NCT05825261
NCT03263130
NCT02796937
NCT04930289
NCT01969344
Lead Sponsor
Kamada, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions